PFE - Pfizer Inc.
| Previous Close | 42.27 |
| Open | 41.99 |
| Bid | 42.0600 x 1200 |
| Ask | 42.0700 x 1200 |
| Day's Range | 41.86 - 42.11 |
| 52 Week Range | 33.20 - 46.47 |
| Volume | 5,878,200 |
| Avg. Volume | 25,493,256 |
| Market Cap | 242.869B |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | 10.61 |
| EPS (TTM) | 3.96 |
| Earnings Date | Jan 29, 2019 |
| Forward Dividend & Yield | 1.44 (3.39%) |
| Ex-Dividend Date | 2019-01-31 |
| 1y Target Est | 45.35 |
- CNBC•2 hours ago
Pfizer, Merck drop after Wall Street downgrades on 'patent cliff' and competition
UBS slashes Pfizer's rating to neutral from buy, citing the so-called "patent cliff" in the coming years that would greatly offset the revenue growth. BMO downgrades Merck to market perform from outperform, saying Wall Street's expectations for the drugmaker are too high given its over-dependence on the drug Keytruda. Shares of Pfizer PFE and Merck MRK fell on Wednesday after Wall Street analysts downgraded the drugmakers on increased competition and the pending loss of patent protection.
- Market Realist•4 hours ago
Is Pfizer Expecting a Rise in Its Expenses in 2019?
Analysts' Ratings for Pfizer Are Mixed ahead of Its Q4 Results(Continued from Prior Part)EPS projections On its third-quarter earnings conference call, Pfizer (PFE) predicted adjusted EPS of $2.98–$3.02 for 2018, a YoY (year-over-year) rise of 13%
- Market Realist•yesterday
How Pfizer’s Research Pipeline Is Set Up ahead of Its Q4 Results
Analysts' Ratings for Pfizer Are Mixed ahead of Its Q4 Results(Continued from Prior Part)Research and development prospects On its third-quarter earnings conference call, Pfizer (PFE) projected that 25–30 new products from its R&D (research and
- Market Realist•yesterday
Johnson & Johnson Releases Its 2018 Results: Revenue Up 6.7%
Johnson & Johnson Releases Its 2018 Results: Revenue Up 6.7%Revenue trends Today, Johnson & Johnson (JNJ) released its fourth-quarter and 2018 financial results. Johnson & Johnson’s net revenue rose ~1% YoY (year-over-year) to $20.4
- InvestorPlace•yesterday
All Signals Are Positive for Buying Abbott Laboratories
Abbott Laboratories (NYSE:ABT) stock rose steadily in the last year and is up around 20% in that time. Though shares hover near yearly highs, thanks to a quick bounce from $66 to $71.42 recently, biotech investors should still consider investing in this company. Last quarter's strong results, plus a recent dividend hike, signal a healthy 2019 year for this medical appliance and equipment firm. Abbott Laboratories will report Q4 results on Jan. 23 that will likely repeat Q3 2018 results, which were posted last October. The firm reported sales of $7.7 billion, up 7.8% on an organic basis. Since divesting its Abbott Medical Optics ("AMO") and integrating St. Jude Medical vascular business, it is more focused on heart and diabetic machines. Diagnostics, medical devices, nutrition, and established pharmaceuticals all grew in the healthy single digits. ### Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. It owes its growth to developments in its medical devices. For example, the U.S. approved the FreeStyle Libre 14-day system, so sales should start adding to results. FreeStyle Libre 2 system and High Sensitive Troponin, available in Europe, will bring healthy geographic diversification to its revenue. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Retail Stocks to Buy for the Rise of Menswear On Dec. 16, 2018, Abbott declared a 32-cent a share quarterly dividend. This increase from 28-cents a share, or up 14.3%, gives investors a forward yield of 1.8%. This is below that of Bristol-Myers Squibb (NYSE:BMY), at 3.27%, Merck & Co. (NYSE:MRK), at 2.9%, or Pfizer (NYSE:PFE), at 3.39%. Medtronic (NYSE:MDT) has a comparable dividend yield of 2.29%. Despite dividend yields below that of comparable medical firms, this is still a bullish signal. Management is demonstrating its confidence in future cash flow growth and rewarding shareholders with income. Plus, the firm pays a higher dividend yield than the bottom 25% of dividend payers in the U.S. (according to simplywall.st). ### Abbott Balance Sheet Analysis Abbott's net worth increased in 2017 to $31.5 billion, but debt also rose, too, to $23.8 billion. This is due to the St. Jude Medical acquisition. Markets do not seem to care about the higher debt because its long term, the debt/equity ratio is only 0.62X, according to MacroTrends. In the drug space, Bausch Health Companies (NYSE:BHC) has a debt/equity of nearly 8x while Mylan N.V. (NASDAQ:MYL) is at 1.2X. The point here is that Abbot can handle the debt due to its healthy debt coverage. Its Operating cash flow of 26% exceeds its over 20% of total debt. Interest payment on the debt is covered by 4.8 times its EBIT. Abbott Laboratories debt levels increased from merger and acquisition activities. (Source: https://simplywall.st) ### Outlook for ABT Stock Synergies from the integration of Abbott's St Jude unit will save on costs. Because management puts an emphasis on improving its underlying gross margin, look for the unit to keep performing better and adding more to profits. The Alere unit, which will bring in $2 billion in revenue for fiscal 2018, will add positively to profits. Last year, Abbott stabilized and integrated the business. With that activity complete, it may concentrate on growing the business. As it happened that the strong flu season will benefit results, sustaining growth will depend on new product introductions from the unit. Based on the six analysts covering ABT stock, the average price target is $79.33, representing upside of 11%. Investors may build a bearish to neutral 10-year DCF Revenue Exit model that assumes revenue slowing in the single digits. Even in that scenario, the model from finbox.io would still suggest a fair value of $73, not far from the recent stock price of ABT. Abbott put a priority on its dividends over debt repayment. Its businesses are growing steadily and the product list is getting bigger. Cash flow growth will let the company meet its dividend payment obligations while paring debt levels over the long-term. ABT stock is suitable for income investors who want to own a growing medical appliances firm at a reasonable price. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Growth Stocks for the Return of the Bull * The 10 Best Index Funds to Buy and Hold * 10 Lithium Stocks to Buy Despite the Market's Irrationality Compare Brokers The post All Signals Are Positive for Buying Abbott Laboratories appeared first on InvestorPlace.
Market Realist•yesterdayIs Pfizer Expected to Impress the Market with Its Q4 Results?
Analysts' Ratings for Pfizer Are Mixed ahead of Its Q4 Results(Continued from Prior Part)Performance in the third quarterIn the third quarter of 2018, Pfizer (PFE) reported revenue of $13.3 billion, a YoY (year-over-year) rise of 1% on a reported
- Market Realist•yesterday
What Do Analysts Recommend for Pfizer ahead of Its Q4 Results?
Analysts' Ratings for Pfizer Are Mixed ahead of Its Q4 ResultsAnalysts’ recommendations Pfizer (PFE) is expected to post its earnings results for the fourth quarter of 2018 on January 29, 2019. Before we discuss the company’s fourth-quarter
- Markit•yesterday
See what the IHS Markit Score report has to say about Pfizer Inc.
# Pfizer Inc ### NYSE:PFE View full report here! ## Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $1.49 billion over the last one-month into ETFs that hold PFE are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Neutral The current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•yesterday
Better Buy: Pfizer vs. AbbVie
Which of these dividend-paying pharmaceutical stocks is the best pick right now?
- Kiplinger•2 days ago
The Dogs of the Dow 2019: 10 Dividend Stocks to Watch
The "Dogs of the Dow" is a simple but successful value investing strategy that many on Wall Street swear by. It's easy: At the beginning of the year, buy the 10 highest-yielding dividend stocks in the Dow Jones Industrial Average. Hold them for a year. Next year, rinse and repeat. While this does result in higher-than-average income, the investment case really is a value one. The idea: A high dividend yield - in the kind of rock-solid blue-chip stocks the Dow tends to hold - implies that shares are oversold. Meanwhile, the continued payment of dividends shows that management remains confident in the company's earnings. Investors thus should profit both from an above-average yield, as well as an eventual recovery in share prices once Wall Street realizes its selling has gone too far. How well does the strategy work? In 2018, the Dogs of the Dow lost just 1.5% on average versus a 5.6% decline for the Dow and a 6.2% drop for the Standard & Poor's 500-stock index. The win marked the Dogs' fourth consecutive year of outperformance. And already in 2019, some Dogs are baring their fangs. Here are the 10 dividend stocks that make up the Dogs of the Dow, listed in order of their dividend yields as of the start of 2019. We also list their current yields, which have shifted a bit in the first few days of this year's trading. ### SEE ALSO: The 25 Best S&P; 500 Stocks of the Past 50 Years
- Motley Fool•2 days ago
3 Stocks That Are Easy to Understand
Keep it simple, shareholders, with these three stocks.
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
Reuters•2 days agoGSK Chairman Hampton to step down ahead of split
The announcement comes a month after GSK's Chief Executive Emma Walmsley announced her boldest plans yet - to split the company into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products. Walmsley, who took the helm in 2017, announced in December that GSK and Pfizer (PFE.N) would combine their consumer health businesses in a joint venture with sales of 9.8 billion pounds ($12.7 billion), 68 percent-owned by the British company, in an all-equity transaction. "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new Chair to oversee this process through to its conclusion over the next few years," Hampton said in a statement.
- Financial Times•2 days ago
[$$] GSK chairman to step down ahead of break-up
The search for Sir Philip’s successor will take up to nine months, according to someone familiar with the process, who said he would have completed about five years on the board when he eventually stepped down. On his watch there had been “a lot of change that needed to happen”.
- Motley Fool•3 days ago
Would Pfizer Shareholders Win With an Acquisition of Amarin?
A Pfizer buyout of Amarin is still just a rumor. But rumors sometimes turn into reality.
- Motley Fool•3 days ago
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
The answer: It's complicated.
- Zacks•5 days ago
Top Stock Reports for Pfizer, Biogen & Schwab
Top Stock Reports for Pfizer, Biogen & Schwab
- Zacks•5 days ago
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
- Zacks•5 days ago
Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress
The index enjoyed another strong week of gains, increasing over three straight sessions.
- Zacks•5 days ago
Baxter (BAX) Gains From Sharesource's Global Success Rates
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
- GuruFocus.com•6 days ago
The Stable Value Stock Is Built to Weather Market Storms
It is hard to say anything about McKesson (MCK) that we have not said before -- it is a high-quality business with extremely cheap shares. McKesson stock is not just cheap -- it's incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.
- Zacks•6 days ago
J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.
- InvestorPlace•6 days ago
3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group
Wednesday was another winner for Wall Street, but just barely. The S&P 500 ended the day up 0.22%, having peeled back from a high of 2,625.786 to close at 2,616.10. The weight of the rally since late December is starting to weigh on investors. Financial stocks, led by bank stocks, carried most of the gain's weight. Bank of America (NYSE:BAC) was up 7.2% after swinging to a record-breaking fourth quarter profit. Yet, had it not been for sweeping bullishness from the financial sector, the overall market may not have ended the day with any gain at all. Ford Motor Company (NYSE:F) fell more than 6% on a disappointing fourth quarter. Snap (NYSE:SNAP) fared even worse, however, losing 13.7% after losing CFO Tim Stone … the second CFO resignation in less than a year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Those disparate results are a microcosm of the environment right now, where the rising tide isn't lifting all boats equally. Going forward, traders will have to be more discriminate, and focus on stock charts like those of Fiserv (NASDAQ:FISV), Pfizer (NYSE:PFE) and PNC Financial Services Group (NYSE:PNC), which are better positioned to make trade-worthy moves. ### Fiserv (FISV) As odd as it may sound to cast a bullish light on Fiserv after it fell more than 4% at one point on Wednesday in response to news that it aims to acquire rival First Data (NYSE:FDC), in most regards the stumble was the capitulation the stock's needed for a while. * 10 Growth Stocks With the Future Written All Over Them Indeed, several clues already suggest that's exactly what happened yesterday. Click to Enlarge • The shape of yesterday's bar is telling in and of itself. After a poor open and then a sharp move to lower lows, the buyers came roaring back later in the day to force a close near the top of the range. The pivot has already been made. • Underscoring the potential capitulation is a huge volume surge. This indicates the last of the would-be sellers were finally flushed out. Now the buyers can start to trickle in without facing a headwind. • Curiously, yesterday's low around $68.50 was also last month's low, and last May's low. The bulls have drawn a line in the sand there. • Still, this is a scenario that requires a little follow-through to erase any lingering doubts that the reversal effort is for real. ### Pfizer (PFE) In yesterday's examination of the market's top three stock charts, the brewing bearishness of Merck (NYSE:MRK) was highlighted, but only because rivals like were also bumping into a headwind. When an entire group of stocks starts to struggle, it generally indicates a secular undertow that won't be easy to stop. In the meantime, Pfizer itself worked its way into a little more technical trouble, losing ground after being unable to press above its key moving averages too … moving averages that have formed bearish crosses while most other stocks are seeing bullish ones. Click to Enlarge • A couple of weeks ago the blue 20-day moving average line fell below the purple 50-day and gray 100-day moving average lines, and the 50-day line is close to breaking below the 100-day line. It all points to accelerating bearishness. • The selling volume has also been greater than the buying volume of late, even if both have been choppy. • The white 200-day moving average line at $40.27 has the potential to act as support should the potential selloff take shape, but there's an interim floor around $42.00 that would have to fail first before any of this weakness matters. ### PNC Financial Services Group (PNC) Finally, though almost all financial stocks were up on Wednesday, too many of them are now too overextended to bother stepping into now. Not PNC Financial Services Group, however. PNC is still closer to its recent low than not, with a whole lot of room to keep climbing. And, the recent chart action says this stock has built a near-perfect launch pad from which PNC will continue to rally. Click to Enlarge • Notice that PNC Financial Services shares have mostly stagnated since late last year, but within the past few days has started to log higher highs and higher closes. • Better yet, Wednesday's pullback to the blue 20-day moving average line was a perfect opportunity for the profit-takers to pile in. They didn't though, overwhelmed by the buyers waiting in the wings. Rising volume confirms more buyers are crawling out of the woodwork. • Zooming out to the weekly chart we can see the December pullback dragged PNC all the way to an established support line that extends back to March's lows. Each brush of that floor has resulted in a decent rebound. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group appeared first on InvestorPlace.
- Associated Press•7 days ago
Court rules against Pfizer in religious discrimination suit
TRENTON, N.J. (AP) — A woman who said she was fired by a major pharmaceutical company because of her religious beliefs won a court victory Wednesday when a state appeals panel ruled that she didn't agree in an online form to waive her rights to sue.
- CNBC Videos•5 days ago
Bulls bet on this biopharma company. Plus, the update on ...
"Halftime Report" traders Jon and Pete Najarian spot unusual options activity in shares of Macy's and Pfizer.
